Chugai Pharmaceutical, a leading Japanese biopharmaceutical company majority-owned by Roche, is dedicated to developing innovative therapies across oncology, immunology, neurology, hematology, ophthalmology, and metabolic diseases. With a strong legacy of co-discovering major biologics like Actemra and Hemlibra, Chugai integrates cutting-edge drug discovery platforms, advanced antibody technologies, and strategic AI partnerships to accelerate development. The company operates globally—from early research and clinical trials to manufacturing—while driving sustainable business practices and expanding its pipeline toward becoming a world-leading innovator by 2030.